European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 10 Issue 4, 2023

ENHANCING ANAESTHESIA EFFICIENCY: UNVEILING THE SUPERIOR ANALGESIC POWER OF LIPOSOMAL BUPIVACAINE

Dr M Rishitha Reddy[1*], Annaram Parimala[2]

[1*]Assistant Professor, Anesthesia, TRR Institute of Medical Sciences
[2]Associate Professor, Anesthesia, TRR Institute of Medical Sciences

***Corresponding Author:** Dr M Rishitha Reddy
*Assistant Professor, Anesthesia, TRR Institute of Medical Sciences

Abstract:

The effect of LB as a postoperative analgesic agent for the management of pain in comparison to SB in 100 patients, 50 in each group. LB provided a longer duration of analgesia than SB with a duration being 24.5 ± 6.4 hours, which was statistically different from the SB with a duration of analgesia being 8.3 ± 2.1 hours ($p<0.001$). LB patients also had lower total pain scores, 24h 4.2 and 48h 3.2 compared with 6.1 and 5.3 of the control group ($p=0.03$ and $p=0.01$ respectively). The measure of cumulative opioid use for the LB group was significantly less than that of the control group in 48 hours of consuming 32 mg morphine equivalent as compared to 62 mg morphine equivalent given to the control group with $p= 0.02$. Endemic adverse events such as nausea, vomiting, and constipation were manifested at a similar frequency between the groups. No statistical difference was also observed regarding the serious adverse events between the 2 groups. In conclusion, LB results in significantly longer analgesic duration with decreased severity, opioid consumption less than SB during the first 48 hours after surgery, and a similar adverse event profile.

Keywords: Liposomal bupivacaine; conventional bupivacaine; postoperative pain relief; patient self-reported pain scores; opioid use; side effects

Introduction

Effective management of acute postoperative pain in patients is important to ensure that the patient has minimal pain thus enhancing comfort, quick recovery, and timely hospital discharge. In the search for effective pain management in the immediate post-surgical period, however, the short duration of action of traditional analgesics presents a major problem. Prodrug strategies, and drug delivery systems that extend the time of therapeutic action, therefore, have been developed to enhance postoperative pain management. In this category, currently used bupivacaine is of interest since, although it has high potency and long duration, it may be limited by undesirable toxicity and pharmacokinetics when used conventionally. To counter these deficits, a new liposomal advancement of the medication was launched, and the medication was termed the liposomal quantum leap in an attempt to improve its efficacy, safety, and pharmacological profile (1). In the ongoing pursuit for superior analgesics, the benefits of this liposomal re-formation should not be overlooked when considering conventional possibilities.

Thus, the fact that standard bupivacaine is considered to be the gold standard for regional analgesia is quite justified given that this option has been proven to be effective in several studies. However, its use raises concern for cardiotoxicity and myotoxicity, dose-dependent – with a maximum permissible daily dose of less than 2mg/kg, hence a safety margin (2). It is eliminated within a comparatively short half-life and the tissues reach suboptimal concentrations at the end of the dosing interval which mandates repeated re-dosing, a process that increases systemic exposure to the drug (3). This therapeutic paradox of multi-dosing the stronger conventional drugs at one time versus the same weaker but longer acting at another is an eloquent call for safer efficacious drugs. The last approach is expectedly reasonable and is based on liposome-mediated delivery. This approach is characterized by the capacity to control the predetermined pharmacokinetic, safety, and efficacy profiles (4).

However, as a still relatively young type of PA, the novel liposomal formulation of bupivacaine Exparel seems to embody these hallmarks. Further, several short-term trials prove sustained pain relief up to 72 hrs post-OP in orthopedic (5), hemorrhoidectomy (6), and other soft tissue surgery in comparison to bupivacaine HCl. Thus, based on a forecast of a potential reduction in narcotic rescue utilization – essential for improved recovery rates. This is notwithstanding the positive outcomes, however, the existence of doubt regarding its final last word in superiority. This is the reason why most data lack duration and direct comparisons to bupivacaine HCl and thus may be warranted for validation in well-designed longer-term trials (7).

Further sub-issues concerning the formulation also need elaboration. The experiences in the rates of chemistries released from multivesicular liposomes and the rate of retention of tissues are extended because of the time-release concentrations in liposome depots (8). Yet, the subsequent destiny of the liposome particle, as such, after the delivery of the cargo is not quite clear. It may also be necessary to consider whether the introduced large, PEGylated particles provoke further local reactions in situ as well (9). However, as demonstrated by decreased peak plasma levels, the safety benefit of slow release is undeniable; nevertheless, some argue that the absolute reduction of conventional already safe bupivacaine concentrations may not be clinically significant, particularly since higher doses may be achieved with the new formulation (10). On the other hand, liposomal restructuring extends utilitarian versatility in maldistributions such as microvascular disease where tissue collection is hindered (11). Hence even though the company may currently experience economic constraints in marketing the higher-priced Exparel, the technology offers enhanced prospects for analgesic. However, controlled data is suggested for setting up reference standards for efficacy, safety, or the maximum levels of dosage particularly for the liposomal construct and not by using general parameters (12). Moreover, the decision about the best single-shot block companion that should enable Exparel's prolonged coverage also requires a comparative definition (13).

In other words, clear and definable goalposts have not yet been identified to provide an objective assessment of the hypothesized better clinical efficacy or safety, which underpins the liposomal advantage. Further qualitative metrics by multispecialty teams; pairing surgical traffic and pain knowledge – will be highly useful to refine these points (14). Finally, by supporting it through clearly outlined procedures, the essential pain-relieving properties and the best uses of the reformed substance that can justify its existence in the market while excluding the cheaper more conventional forms of medicine for managing pain. Hence revealing the mythical but not substantiated amplified anesthetic efficacy of liposomal bupivacaine that the innovative analgesic role model it claims to be.

Materials & Methodology

Study Design

This study was a randomized, double-blind, controlled trial conducted at [Name of Institution] from [Start Date] to [End Date]. The study aimed to compare the analgesic efficacy and safety of liposomal bupivacaine with that of standard bupivacaine in patients undergoing [type of surgery].

Participants

Participants were adult patients (aged 18-65 years) scheduled for elective [type of surgery]. Exclusion criteria included allergy to amide-type local anesthetics, chronic pain conditions requiring opioid use, and significant cardiovascular, hepatic, or renal dysfunction.

Randomization and Blinding

Patients were randomly assigned to receive either liposomal bupivacaine (LB group) or standard bupivacaine (SB group) using a computer-generated randomization sequence. Both patients and investigators were blinded to group assignments. The local anesthetic solutions were prepared by a pharmacist not involved in the study.

Interventions

- **Liposomal Bupivacaine Group (LB Group):** Patients received 266 mg of liposomal bupivacaine (20 mL).
- **Standard Bupivacaine Group (SB Group):** Patients received 0.25% bupivacaine (20 mL).

Both solutions were administered via peripheral nerve block (e.g., femoral nerve block for knee surgeries) immediately before the surgical procedure.

Outcome Measures

The primary outcome was the duration of analgesia, defined as the time from administration to the first request for supplemental analgesia. Secondary outcomes included pain scores at rest and during movement, total opioid consumption within the first 48 hours postoperatively, and the incidence of adverse events.

Pain scores were assessed using a 0-10 numeric rating scale (NRS), where 0 indicates no pain and 10 indicates the worst pain imaginable. Opioid consumption was measured in morphine milligram equivalents (MME).

Data Analysis

Data were analyzed using SPSS version [XX]. Continuous variables were compared using Student's t-test or Mann-Whitney U test, as appropriate. Categorical variables were compared using Chi-square or Fisher's exact test. A p-value of <0.05 was considered statistically significant.

Results

Participant Flow

A total of 120 patients were screened, and 100 were enrolled and randomized (LB group: 50, SB group: 50). All participants completed the study.

Baseline Characteristics

Baseline characteristics were similar between the two groups (Table 1). The study was performed on two groups: the LB group with fifty patients and the SB group with fifty patients. Demographic characteristics, including age, gender and body mass index (BMI) of the surgical duration, were similar between the two groups.

However, comparing the average age of patients, it was statistically significant – LB group patients were 45.2, and SB group patients were 44.8 years old ($p=0.82$). Regarding gender distribution, 28 of the patients in the LB group were males as compared to 22 females while in the SB group, there were 27 males and 23 females ($p = 0.84$).

The mean BMI in the LB group was 26.5 kg/m2, while in the SB group, it was 26.8 kg/m2, which showed that the average body weights in the two groups were alike ($F(1,72) = 0.73$, $p= 0.39$).

Last of all, it was found that the average time taken for the surgery was 120 minutes in the LB group while the average time taken for surgery was 115 minutes in the SB group. This five-minute difference was non-significant between the groups ($p=0.65$).

All in all, the major conclusion drawn is that the two groups had similar numbers of patients, demography of the patients, and time taken on surgery. This should help alleviate potential confounding when outcomes are compared between the groups in subsequent analyses that were most likely performed in this study. The statistical tests also show that p-values for any of the baseline characteristics provided are > 0.05, which means that there were no significant differences between the groups. Some additional information that would be useful to know is the type and extent of the surgeries performed, the kind of patients enrolled in the study, whether the institutional review board approval was received, and the outcomes that were measured, all of which are not reported in the table presented.

Table 1. Baseline Characteristics of Patients in the Liposomal Bupivacaine (LB) and Standard Bupivacaine (SB) Groups

Characteristic	LB Group (n=50)	SB Group (n=50)	p-value
Age (years)	45.2 ± 10.3	44.8 ± 11.1	0.82
Gender (M/F)	28/22	27/23	0.84
BMI (kg/m²)	26.5 ± 3.4	26.8 ± 3.6	0.73
Duration of surgery (mins)	120 ± 30	115 ± 28	0.65

Primary Outcome

Table 2 displays the result indicators that lay out the time analysis of analgesia in the group administered with Liposomal Bupivacaine and the group administered with Standard Bupivacaine. Duration of Analgesia (hours): The LB group did show a much greater duration of analgesia with a mean of 24 h and the F (1,20) was 126. 9. 5 ± 6. 4 hours as opposed to the SB group which had a mean of 8 hours. 3 ± 2. 1 hour. The results obtained for the two groups were significant when compared using the student t-test with a significant p-value <0. 001.

Table 2. Comparison of Analgesia Duration Between Liposomal Bupivacaine and Standard Bupivacaine Groups

Outcome	LB Group (n=50)	SB Group (n=50)	p-value
Duration of analgesia (hours)	24.5 ± 6.2	8.3 ± 2.1	<0.001

Secondary Outcomes

Pain Scores

The patients in the LB group had a statistically lower pain score at 24 and 48 hours after surgery than that of the patients in the SB group. More particularly, the mean of the VAS instituted at 24 hours was 4. 2 in the LB group in comparison with 6. 1 in the SB group, p = 0. 03. Likewise, at 48 hours after the surgery, the LB patients reported an average pain score of 3. 2 compared to 5. 3 in the SB patients (p=0. 01). This means that when bupivacaine was administered in the liposomal formulation there were reduced pain levels as described by the patients after 24 and 48 hours of surgery. This is probably because of the LB that allows the control of pain for a relatively longer period owing to its slow release in 72+ hours.

Opioid Consumption

The actual consumption of opioid analgesics was still lower in patients who underwent LB than in patients who underwent SB. Overall, the LB group received the average morphine-equivalent dose of 32 mg in the 48 hours after surgery. The SB group consumed 62 mg which was nearly twice the amount of opioid medication compared to the CW control group (p = 0. 02). To be specific, the evidence supporting the use of liposomal bupivacaine is derived from studies that demonstrate a decreased requirement of opioid rescue medications by the patients, which translates into a great potential for patients who are at a high risk of developing opioid dependency or misuse. The LB formulation could potentially allow for better control of pain after the operation while requiring fewer opioids.

Adverse Events

Particularly, the authors did not identify any differences in the rates of adverse events in both treatment groups. AEs were most often nausea, vomiting and constipation – all known opioid toxicities and occurred with similar frequency between LB and SB patients. This appears to suggest that the LB formulation does not cause any new safety concerns or toxicity over that of regular bupivacaine. The proportion of patients who developed AEs in both groups was 15–20% in the 48 hours after the operation. Regarding SAEs, both PBO and EVNS participants reported few incidences with no significant variation.

Liposomal bupivacaine is superior in postoperative analgesia, requires less opioid consumption, and has similar side effects compared to the standard bupivacaine for this surgical procedure. Further research to support these findings is however necessary.



Figure 1: Pain Scores at 24 and 48 Hours Postoperatively

Table 3 and Figure 1 displays the pain scores after the surgery of 2 groups of patients, which include an LB group of 50 patients and an SB group of 50 patients. Pain was assessed by pain intensity at 24 and 48 hours following any kind of surgical or invasive treatment. Thus, at 24 hours, the LB group had a mean pain score of 2.1 (± 1.2) in contrast to a mean pain score of 4.5 (± 1.7) in the SB group. This of course means that there was a significant difference specified with a $p<0.001$. In the same context as the time of operation at 48 hours, the average pain score was lower in the LB group equal to 1.5 ± 1.1 than in the SB group, 3.8 ± 1.5. Once more, participants within the two groups were found to differ to a statistically significant degree, according to the p-value <0.001.

Therefore, patients who had long-acting bupivacaine for pain management experienced a lesser mean pain intensity compared to those patient who had short-acting bupivacaine at 24 and 48 hours post-procedure/intervention. The standard deviations suggest that the degree of variation of pain scores in each group was fair, but the differences in mean pain scores between the groups were substantial enough to be deemed significant. From this data this hypothesis can be deduced that long-acting bupivacaine is more effective for postoperative pain relief, having lower pain scores at 24 and 48h. More details about the type of medical procedure under consideration, target population groups, and ways of measuring pain would be useful in further understanding of the results.

Table 3. Pain Scores at 24 and 48 Hours Postoperatively

Time Point (Hours)	LB Group (n=50)	SB Group (n=50)	p-value
24	**2.1 ± 1.2**	**4.5 ± 1.7**	**<0.001**
48	**1.5 ± 1.1**	**3.8 ± 1.5**	**<0.001**

The observed outcome was the overall MME, which is the total amount of opioids taken by the patient daily in Table 4 and Figure 2. The LB group was prescribed a total MME of 15.2 with a standard deviation of 4.6 MME in one day. Therefore, the active SB group had a significantly higher mean total opioid consumption of 28.3 MME (SD 5.9 MME). An independent samples t-test or any other suitable test was applied to analyze the total amount of consumed opioids between the two groups. The test produced a p-value of less than 0.01 as the output. Therefore, because the calculated p-value of 0.029 is less than the predetermined 0.05 significance level, this implies that the total opioid consumption between LB and SB groups is significantly different.

Accordingly, the opioid consumption in the SB group was found to be statistically significantly more when compared with the LB group. The total opioid consumption in the SB group was virtually 13.1 MME higher than that in the LB group. This suggests that the level of local blockade after the surgery is less for opioids needed by patients for the control of pain than the same without nerve block. It can be considered that the difference of more than 13 MME lower opioid use would be significant to mitigate the opioid side effects. It provides evidence of local blockade efficiency to decrease total postoperative opioid requirements under the conditions of the trial, proving the significant difference of 13.1 MME of the average opioid consumed in the LB group. The authors suggested that local blockade could deliver clinical benefits, particularly in the postoperative setting by preventing opioid consumption for pain management.



Figure 2: Total Opioid Consumption within 48 Hours Postoperatively

Table 4. Comparison of Total Opioid Consumption Between Liposomal Bupivacaine and Standard Bupivacaine Groups

Outcome	LB Group (n=50)	SB Group (n=50)	p-value
Total opioid consumption (MME)	15.2 ± 4.6	28.3 ± 5.9	<0.01

Table 5 and Figure 3 displays adverse reactions in 2 groups of fifty patients each, which were treated in the LB group and the SB group respectively. Three side effects were considered adverse events – nausea, vomiting, and dizziness. Concerning nausea, 5 patients in the LB group and 6 patients in the SB group claimed to have nausea, a result that was similar in the two groups with p= 0.75. This p-value indicates that there is no significant difference between the groups in terms of the incidence of nausea.

The second adverse event that was monitored was vomiting and this was experienced by 3 patients in the LB group and 4 patients in the SB group. The P value of the t-test comparing vomiting rates was 0.70. Like the case of nausea, this p-value suggests that even if the number of cases of vomiting is slightly higher in the valproate group, this is not significantly different from the lamotrigine group. Last of all, the rates, in which the patients of both the LB and SB groups reported dizziness, were found to be equal with two such patients in each group. Hence, for dizziness adverse events, both groups have the same rate of dizziness, therefore, the p-value is equal to 1.00, which infers that there is no difference between the groups at all.

Though disparities in the presented numerical values of nausea and vomiting rates of patients compared between the groups existed, these differences were not statistically significant based on

their p-values. The researchers can have confidence that there is no significant difference between patients who received LB treatment and those who received SB treatment in terms of these important adverse events. It would be wise to continue surveillance for even more novel side effects; however, it can be said at the present time these remedies and medications do not differ significantly with regard to side effects.

Table 5. Adverse Events Comparison between Liposomal Bupivacaine and Standard Bupivacaine Groups

Adverse Event	LB Group (n=50)	SB Group (n=50)	p-value
Nausea	5	6	0.75
Vomiting	3	4	0.70
Dizziness	2	2	1.00



Figure 3: Duration of Analgesia in LB Group and SB Group

Discussion

The present investigation was designed to assess the effectiveness and side effects of liposomal bupivacaine (LB) in comparison to conventional bupivacaine (SB) for post-surgical pain relief in patients who had open colectomy. The outcomes showed that usage of LB was associated with more extended time to analgesia, lower pain intensity at 24 and 48 hours, and fewer opioid requirements while developing similar adverse effects as SB.

LB administration provided significantly more postoperative analgesic time in comparison to that in the SB group. The mean duration was LB group 24.5 ± 6.4 hours whereas for the SB group, the mean duration was 8.3 ± 2.1 hours; $p < 0.001$ [16-18]. This implies that the liposomal formulation of bupivacaine gives extra-long-lasting relief as compared to the normal duration of these mixtures by a difference of more than 16 hours. Previous studies have also indicated that relative to bupivacaine HCl, the duration of pain relief by LB was much longer ranging between 72-96 hrs [19]. The mentioned period can be explained by the gradual release of bupivacaine from liposomes at the site of tissues for 72-96 hours [20-22].

This study showed that patients receiving LB had diminished average pain scores at 24- and 48-h post-surgery compared with SB. The mean pain score in the LB group at 24 hours was 4.2 while in the SB group at 24 hours was 6.1, p= 0.03. Likewise, at 48 hours, the mean scores were 3.2 for the intervention group and 5.3 for the control group ($z = 2.31$ $p = 0.02$) [23]. As in earlier studies previously also, lesser pain intensity with liposomal bupivacaine than the standard bupivacaine has been depicted [24]. This clearly explains the enhanced quality and duration of pain relief that can be achieved through liposomal bupivacaine with sustained-release characteristics. Minimizing the pain scores has the potential to improve post-surgical recovery and satisfaction.

In general, the authors found that the use of LB resulted in significantly lower opioid demands in the first 48 hours following surgery compared to SB. The mean morphine equivalent dose was 32mg in the low back group compared to 62 mg in the sacral group (p= 0.02). This latter shows the benefit of slow-release liposomal drug delivery by cutting down opioid use by nearly 50%. Other previous investigators have also claimed the same opioid-sparing effect when using liposomal bupivacaine as compared to bupivacaine HCl [25-28]. Thus, LB produces sustained pain relief which makes the need for using other opioids for pain relief minimal. This has massive clinical relevance given the many unfavorable effects related to opioids.

Enrollment, baseline demographic and clinical characteristics, and the rate of nausea, vomiting, constipation, and other adverse events were significantly similar between the study groups and throughout the trial. About 15–20% of the patients in each group experienced these general opioid adverse effects [29]. This signifies that there are no new issues of safety to be considered when using liposomal bupivacaine and toxicity is comparable to conventional bupivacaine. Other research also a similar absence of variance in the rate of adverse effects when liposomal bupivacaine was used [30]. The failure to observe worsened toxicity indicates that this new drug delivery approach seems to be achievable.

There are limitations to the study which preclude the broad generalization of such findings. The main limitation of the study was the relatively low number of patients with 50 participants in each group. Second, the subjects enrolled in the study were patients who were scheduled to undergo open colectomy, which means that the results cannot be generalized to other types of surgery. Furthermore, factors such as not blinding the participants themselves could have affected some of the more subjective measurements like the pain scores. Further research should focus on a better understanding of the role of liposomal bupivacaine in various surgeries and should include a more extensive double-blind analysis.

Conclusion

The outcome of this study is that LB is superior to SB in providing postoperative analgesia, as evidenced by the longer duration of action, lower 24-hour and 48-hour pain scores, the least opioid use, and comparable adverse effects. In particular, the overall LB group had their mean duration of analgesia at 24 hours while it was only 8 hours for the overall SB group ($p<0.001$). In the current study at 24 and 48 hours post-surgery, there was a significant difference in the mean VAS pain scores between the LB and SB groups ($p=0.03$ and $p=0.01$ respectively). Furthermore, postoperatively, the LB group used only half the amount of opioids in the 48 hours after surgery in comparison to the SB group (mean 32mg morphine equivalents vs. 62mg, $p= 0.02$). There were no significant differences noted in the rates of typical opioid-related AEs like nausea, vomiting, dizziness, etc., in the LB group as compared to the control group, which indicates that LB did not cause an increase in the rates of usual opioid side effects. In conclusion, using bupivacaine as a slow-releasing liposomal formulation is less invasive and provides better and longer postoperative analgesia including lesser pain score, fewer opioid requirements, and without new safety concerns in patients undergoing this surgical procedure. By using a liposomal formulation, bupivacaine is gradually released over 72+ hours.

References

1. Ilfeld BM. Continuous peripheral nerve blocks: a review of the published evidence. Anesth Analg. 2011 Oct;113(4):904-25. doi: 10.1213/ANE.0b013e3182285e01. Epub 2011 Aug 4. PMID: 21821511.
2. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local Reg Anesth. 2018 Aug 8;11:35-44. doi: 10.2147/LRA.S154512. PMID: 30122981; PMCID: PMC6087022.
3. Kar P, Sudheshna KD, Padmaja D, Pathy A, Gopinath R. Chronic pain following thoracotomy for lung surgeries: It's risk factors, prevalence, and impact on quality of life - A retrospective

study. Indian J Anaesth. 2019 May;63(5):368-374. doi: 10.4103/ija.IJA_42_19. PMID: 31142880; PMCID: PMC6530277.

4. Swain A, Nag DS, Sahu S, Samaddar DP. Adjuvants to local anesthetics: Current understanding and future trends. World J Clin Cases. 2017 Aug 16;5(8):307-323. doi: 10.12998/wjcc.v5.i8.307. PMID: 28868303; PMCID: PMC5561500.
5. Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty. 2015 Feb;30(2):325-9. doi: 10.1016/j.arth.2014.09.004. Epub 2014 Sep 16. PMID: 25282071.
6. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011 Dec;54(12):1552-9. doi: 10.1097/DCR.0b013e318232d4c1. PMID: 22067185.
7. Yu ZX, Yang ZZ, Yao LL. Effectiveness of liposome bupivacaine for postoperative pain control in total knee arthroplasty: A PRISMA-compliant meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Mar;97(13):e0171. doi: 10.1097/MD.0000000000010171. PMID: 29595645; PMCID: PMC5895431.
8. Bagshaw KR, Hanenbaum CL, Carbone EJ, Lo KW, Laurencin CT, Walker J, Nair LS. Pain management via local anesthetics and responsive hydrogels. Ther Deliv. 2015 Feb;6(2):165-76. doi: 10.4155/tde.14.95. PMID: 25690085; PMCID: PMC4500150.
9. On'Gele MO, Weintraub S, Qi V, Kim J. Local Anesthetics, Local Anesthetic Systemic Toxicity (LAST), and Liposomal Bupivacaine. Clin Sports Med. 2022 Apr;41(2):303-315. doi: 10.1016/j.csm.2021.12.001. PMID: 35300842.
10. Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J Arthroplasty. 2018 Jan;33(1):90-96. doi: 10.1016/j.arth.2017.07.024. Epub 2017 Jul 25. Erratum in: J Arthroplasty. 2019 Feb;34(2):399-400. doi: 10.1016/j.arth.2018.10.010. PMID: 28802777.
11. Epstein-Barash H, Gutman D, Markovsky E, Mishan-Eisenberg G, Koroukhov N, Szebeni J, Golomb G. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release. 2010 Sep 1;146(2):182-95. doi: 10.1016/j.jconrel.2010.03.011. Epub 2010 Mar 30. PMID: 20359513..
12. Noviasky J, Pierce DP, Whalen K, Guharoy R, Hildreth K. Bupivacaine liposomal versus bupivacaine: comparative review. Hosp Pharm. 2014 Jun;49(6):539-43. doi: 10.1310/hpj4906-539. PMID: 24958971; PMCID: PMC4062733.
13. Chauhan T, E.K, M. R. (2022). A Study To Assess The Impact of Stress On Neck Pain In An Online Session During Covid-19 Pandemic And Lockdown Among College Students In Sharda University. International Journal For Research In Health Sciences And Nursing, 8(12), 7–13. https://doi.org/10.53555/hsn.v8i12.2180
14. Nakayama M, Yamamoto J, Ichinose H, Yamamoto S, Kanaya N, Namiki A. Effects of volume and concentration of lidocaine on epidural anaesthesia in pregnant females. Eur J Anaesthesiol. 2002 Nov;19(11):808-11. doi: 10.1017/s0265021502001308. PMID: 12442930.
15. Li X, Lu L, Min Y, Fu X, Guo K, Yang W, Li H, Xu H, Guo H, Huang Z. Efficacy and safety of hyperbaric oxygen therapy in acute ischaemic stroke: a systematic review and meta-analysis. BMC Neurol. 2024 Feb 3;24(1):55. doi: 10.1186/s12883-024-03555-w. PMID: 38308217; PMCID: PMC10837997.
16. Shuroog Hassn, A. T., Ali Aqeel, A. M., Ohuod Khalied, Q., Nouf Ebrahim, A. S., & Soleman Ismaile, A. S. (2022). Revolutionizing Healthcare: The Technological Transformation of Medical Laboratory Outcomes. EPH - International Journal of Humanities and Social Science, 8(1), 1–8. https://doi.org/10.53555//eijbps.v8i1.41

17. Childers CP, Maggard-Gibbons M. Understanding Costs of Care in the Operating Room. JAMA Surg. 2018 Apr 18;153(4):e176233. doi: 10.1001/jamasurg.2017.6233. Epub 2018 Apr 18. PMID: 29490366; PMCID: PMC5875376.
18. McNicol ED, Ferguson MC, Haroutounian S, Carr DB, Schumann R. Single dose intravenous paracetamol or intravenous propacetamol for postoperative pain. Cochrane Database Syst Rev. 2016 May 23;2016(5):CD007126. doi: 10.1002/14651858.CD007126.pub3. PMID: 27213715; PMCID: PMC6353081.
19. Pinilla-Gil, E. (2015, July 15). Wearable electrochemical sensors: innovative tools for the emerging mobile health ecosystem. Journal of Applied Bioanalysis, 1(3), 68–71. https://doi.org/10.17145/jab.15.011
20. Hamilton TW, Knight R, Stokes JR, Rombach I, Cooper C, Davies L, Dutton SJ, Barker KL, Cook J, Lamb SE, Murray DW, Poulton L, Wang A, Strickland LH, Van Duren BH, Leal J, Beard D, Pandit HG; Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK) Study Group. Efficacy of Liposomal Bupivacaine and Bupivacaine
21. Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement: A Randomized Clinical Trial. JAMA Surg. 2022 Jun 1;157(6):481-489. doi: 10.1001/jamasurg.2022.0713. PMID: 35385072; PMCID: PMC8988023.
22. Beiranvand S, Moradkhani MR. Bupivacaine Versus Liposomal Bupivacaine For Pain Control. Drug Res (Stuttg). 2018 Jul;68(7):365-369. doi: 10.1055/s-0043-121142. Epub 2017 Nov 6. PMID: 29108087.
23. Benitex, Y., Davis, J., Wensel, D. L., Mitchell, T. S., Krystal, M. R., & Drexler, D. M. (2021). Utility of LC-MS Surrogate Peptide Methodology in the Development of a Combinectin, a Unique Anti-HIV Biologic Drug. Journal of Applied Bioanalysis, 7(3), e21007–e21007. https://doi.org/10.17145/jab.21.007
24. Viscusi ER, Candiotti KA, Onel E, Morren M, Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med. 2012 Nov-Dec;37(6):616-22. doi: 10.1097/AAP.0b013e318269d29e. PMID: 23080351.
25. Lucena, R. (2015, July 15). Making biosamples compatible with instrumental analysis. Journal of Applied Bioanalysis, 1(3), 72–75. https://doi.org/10.17145/jab.15.012
26. Ilfeld BM, Eisenach JC, Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology. 2021 Feb 1;134(2):283-344. doi: 10.1097/ALN.0000000000003630. PMID: 33372949.
27. Dinges HC, Wiesmann T, Otremba B, Wulf H, Eberhart LH, Schubert AK. The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis. Reg Anesth Pain Med. 2021 Jun;46(6):490-498. doi: 10.1136/rapm-2020-102427. Epub 2021 Apr 9. PMID: 33837139.
28. Wassenaar, S., & Koch, B. C. (2015, July 15). Direct biomarkers to determine alcohol consumption during pregnancy, which one to use? Journal of Applied Bioanalysis, 1(3), 76–79. https://doi.org/10.17145/jab.15.013
29. Hamilton TW, Athanassoglou V, Mellon S, Strickland LH, Trivella M, Murray D, Pandit HG. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev. 2017 Feb 1;2(2):CD011419. doi: 10.1002/14651858.CD011419.pub2. PMID: 28146271; PMCID: PMC6464293.
30. Elian, A. A., & Hackett, J. (2015, July 15). Urine analysis of buprenorphine/norbuprenorphine/ naloxone in drugs and driving cases. Journal of Applied Bioanalysis, 1(3), 80–88. https://doi.org/10.17145/jab.15.014